Women who take selective serotonin reuptake inhibitors (SSRIs) while pregnant may be doubling their unborn child’s risk for persistent pulmonary hypertension, according to new research.
Women who take selective serotonin reuptake inhibitors (SSRIs) while pregnant may be doubling their unborn child’s risk for persistent pulmonary hypertension, according to new research.
Helle Kieler, MD, PhD at the Karolinska University Hospital in Solna, Sweden, and colleagues conducted a population-based cohort study that included more than 1.6 million births. They discovered that SSRI exposure in the second half of pregnancy resulted in a twofold increased risk for persistent pulmonary hypertension compared to infants whose mothers did not use SSRIs. The absolute risk was 3 infants per 1,000 exposed.
Risk was similar among SSRIs, with the lowest risk associated with escitalopram (adjusted odds ratio=1.3), followed by fluoxetine, citalopram, paroxetine, and sertraline. Paroxetine had the highest adjusted odds ratio (2.8). Gestational size and caesarean delivery did not modify the effects of the medications during late pregnancy.
For the analysis, maternal health status and list of diseases during pregnancy, including psychiatric illness, was obtained. Kieler et al. also collected information on the pregnancy and birth, incidence of persistent pulmonary hypertension, and whether the woman filled a prescription for SSRIs. Researchers noted recorded whether prescriptions were ever used in pregnancy (three months before the start of pregnancy through birth), used in late pregnancy only (anytime after 140 days following the start of pregnancy through birth), or used in early pregnancy only (three months prior to pregnancy through day 55 of pregnancy).
Kieler and colleagues found that fewer women filled a prescription in late pregnancy as compared to those who filled a prescription in early pregnancy only (0.7% versus 1.1%). Antidepressant use in early pregnancy only also resulted in a slightly higher risk of persistent pulmonary hypertension. The odds ratios for specific medications ranged from 0.3 to 1.9.
“Persistent pulmonary hypertension of the newborn is a rare disease and the absolute risks for this outcome for infants to mothers using SSRIs was as low as three infants per 1000 exposed,” the authors wrote. “However, as the risk in association with treatment in late pregnancy seems to be more than doubled, we recommend caution when treating pregnant women with SSRIs.”
“It is essential to plan the treatment and to weigh the risks of persistent pulmonary hypertension of the newborn when treating women in late pregnancy with those of relapse of depression and neonatal abstinence syndrome if therapy is interrupted,” Kieler et al. added. “For women where treatment with an SSRI is the only or best option, the choice of substance seems to be of minor importance.”
Reference:
Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2011; 344:d8012.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Unveiling the complexities of preterm birth risk from nativity, ethnicity, and race
March 22nd 2024A recent study dissected the relationships between maternal nativity, ethnicity, and race in influencing preterm birth rates, shedding light on disparities and suggesting avenues for future research.
Read More
Study reveals link between opioid dosage and spontaneous preterm birth risk
February 21st 2024Recent research highlighted an association between the total dose of prescribed opioids during pregnancy and the heightened risk of spontaneous preterm birth, emphasizing the need for judicious opioid use in pain management for expectant mothers.
Read More